A similar trial by Goekoop-Ruiterman YP et al. found an increase in the risk of serious infections following treatment with anti TNF agents (Goekoop-Ruiterman et al., 2005)Schneeweiss et al. performed a prospective cohort study and noted that the risk of serious bacterial infections in those treated with anti-TNF agents was high compared to users of DMARDs and MTX (Schneeweiss et al., 2007). The gene discussed is TNF; the disease is infection.